Publications by authors named "Pica R"

Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.

View Article and Find Full Text PDF

Introduction: Usually ipsilateral fractures of the femur and tibia are not compatible with good results and require surgery. The unsatisfactory results are more likely due to complex patterns of fractures, compromised soft tissue, associated ligament injuries, and concomitant vital organ injuries. There are many classifications to describe this type of fracture but none of them is a prognostic classification.

View Article and Find Full Text PDF

Health-related quality of life (HRQoL) represents one of the most concerning aspects for cancer patients. The Healthy Eating Index (HEI) is an a priori diet quality index directly associated with health outcomes and HRQoL in cancer survivors in North American populations. We evaluated, in a Mediterranean population, the baseline associations between HEI-2015 and HRQoL in 492 women with breast cancer recruited in a DEDiCa lifestyle trial.

View Article and Find Full Text PDF

Objective: To report cross-sectionally serum levels of 25-hydroxyvitamin D [25(OH)D] in women living in Italy within 12 months from breast cancer (BC) diagnosis.

Methods: Baseline data were obtained from 394 women diagnosed with primary BC, enrolled from 2016 to 2019 in a lifestyle trial conducted in Italy. Subjects' characteristics were compared between two 25(OH)D concentrations (hypovitaminosis D<20 and ≥20 ng/mL) with the Chi-squared test or Fisher's exact test for small-expected counts.

View Article and Find Full Text PDF

Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and safety of UST in patients with UC in a real-world setting.

Research Design And Methods: This is a multicenter, retrospective, observational cohort study.

View Article and Find Full Text PDF

Background: Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety in Italian UC patients.

Research Design And Methods: A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score.

View Article and Find Full Text PDF

Background: Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.

Research Design And Methods: Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity.

View Article and Find Full Text PDF

Local antibiotic delivery strategies have been increasingly employed for the prevention of fracture-related infections (FRIs). The aim of this study is to evaluate the efficacy and safety of antibiotic-coated implants in the prevention of FRIs after surgical treatment in patients with increased infectious risk. A retrospective observational study has been conducted on patients with upper and lower limb fractures treated with internal fixation or prosthetic replacements, using a gentamicin coated nail (CN) and/or antibiotic-loaded hydrogel applied to the implant of choice (ALH).

View Article and Find Full Text PDF
Article Synopsis
  • The Mediterranean diet, low dietary glycemic index (GI), and dietary inflammation index (DII®) are linked to a lower risk of breast cancer incidence and mortality.
  • A study investigated the impact of one-year nutrition counseling focused on the Mediterranean diet, with or without low-GI carbohydrate guidance, on DII in women with breast cancer participants from the DEDiCa trial.
  • Results showed significant increases in Mediterranean diet adherence and decreases in GI and DII scores after one year, indicating that adherence to these dietary patterns can lower inflammation, which may be beneficial for cancer prognosis.
View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to compare the efficacy and safety of four adalimumab (ADA) biosimilars in patients with inflammatory bowel disease (IBD) after they were switched from the original ADA for non-medical reasons.
  • Out of 153 IBD patients, 81% maintained clinical remission during a 12-month follow-up, and there was no significant difference in outcomes among the four biosimilars.
  • However, patients with ulcerative colitis (UC) experienced a higher loss of remission compared to those with Crohn's disease (CD), indicating that switching biosimilars in UC patients may require careful evaluation.
View Article and Find Full Text PDF

Introduction: Injuries around the elbow pose a challenging problem for orthopaedic surgeons. The complex bony architecture of the joint should be restored and the thin soft tissue envelope needs to be handled with meticulous care. Elbow instability is a complication seen after dislocations and fractures of the elbow and remains a treatment challenge.

View Article and Find Full Text PDF
Article Synopsis
  • Adalimumab (ADA) biosimilars are more affordable options for treating inflammatory bowel disease (IBD), but data comparing their effectiveness and safety remains limited.* -
  • A study analyzed 533 IBD patients in Italy, measuring clinical activity, remission induction, and safety across four ADA biosimilars (SB5, ABP501, GP2017, and MSB11022).* -
  • Results showed high clinical remission rates (79.6% for new biologics and 81.0% for patients switched from the ADA originator) with low adverse events (6.7%), indicating similar efficacy and safety among the different biosimilars.*
View Article and Find Full Text PDF

Background: To compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy.

Research Design And Methods: Three hundred and eighty IBD outpatients were retrospectively evaluated. The primary endpoint was to compare the two IFX biosimilars in terms of reaching and maintenance of remission at any timepoint.

View Article and Find Full Text PDF

Introduction And Aim: Biologic treatment - particularly with the anti-TNF molecules - is frequently used in clinical practice to treat the severe form for both chronic rheumatic diseases and inflammatory bowel diseases. The immunosuppression induced by biologic therapies increases the risk of infections, including tuberculosis, as well as hepatitis B virus (HBV) reactivation may occur in inactive carriers or occult HBV infection (OBI) subjects during biologic therapy. This study aimed to update data on HBV prevalence and reactivation in patients receiving biologic therapy for either chronic rheumatic diseases or IBD, and to describe their management in clinical practice.

View Article and Find Full Text PDF

SARS-CoV-2 is the etiological agent of the current pandemic worldwide and its associated disease COVID-19. In this review, we have analyzed SARS-CoV-2 characteristics and those ones of other well-known RNA viruses viz. HIV, HCV and Influenza viruses, collecting their historical data, clinical manifestations and pathogenetic mechanisms.

View Article and Find Full Text PDF

Background: The proton pump inhibitors (PPIs), used to reduce gastric acid secretion, represent one of the most widely used pharmaceutical classes in the world. Their consumption as a risk factor for the evolution of severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been investigated as well as the mortality of these patients. These risks also appear to be linked to the duration and the dosage.

View Article and Find Full Text PDF

Colonic lipomatous polyps are often an incidental finding during colonoscopy. Generally, these types of polyps can cause gastrointestinal bleeding when they are larger than 4 cm in size. Some case reports have documented the occurrence of overlying adenomatous formations in the apical portion, as well as ulcerated mucosa.

View Article and Find Full Text PDF
Article Synopsis
  • Infliximab and adalimumab are both commonly used medications for treating Crohn's disease and ulcerative colitis, and this study aimed to evaluate their long-term effectiveness and safety in real-life clinical settings.
  • A total of 712 patients were reviewed, showing that both treatments maintained clinical remission similarly in Crohn's disease, but infliximab showed better results for ulcerative colitis.
  • Adalimumab had a significantly lower rate of adverse events compared to infliximab, making it a potentially safer option for patients.
View Article and Find Full Text PDF

Illicit substances are widely used all over the world. Among them, crack cocaine results to be the most used drug for the fact that it can be taken in different ways, such as inhaled or intravenous. Pulmonary complications are well known in people snorting it, mostly due to contamination with other substances contained in the objects able to infuse the drug.

View Article and Find Full Text PDF

In the last decades, the comprehension of the pathophysiology of bone metabolism and its interconnections with multiple homeostatic processes has been consistently expanded. The branch of osteoimmunology specifically investigating the link between bone and immune system has been developed. Among molecular mediators potentially relevant in this field, vitamin D has been recently pointed out, and abnormalities of the vitamin D axis have been described in both in vitro and in vivo models of inflammatory bowel diseases (IBD) and arthritis.

View Article and Find Full Text PDF

Objective: Ustekinumab (UST) is an anti-IL12/23 antibody for the treatment of Crohn's Disease (CD). The aim of this study was to compare the efficacy and safety of UST in a large population-based cohort of CD patients who failed previous treatment with other biologics.

Patients And Methods: 194 CD patients (108 males and 86 females, mean age 48 years (range 38-58 years) were retrospectively reviewed.

View Article and Find Full Text PDF

Healthy lifestyles are associated with better health-related quality of life (HRQoL), favorable prognosis and lower mortality in breast cancer (BC) survivors. We investigated changes in HRQoL after a 12-month lifestyle modification program in 227 BC survivors participating in DEDiCa trial (Mediterranean diet, exercise, vitamin D). HRQoL was evaluated through validated questionnaires: EQ-5D-3L, EORTC-QLQ-C30 and EORTC QLQ-BR23.

View Article and Find Full Text PDF
Article Synopsis
  • * The case presented involves a woman who experienced abdominal pain and faintness 12 hours post-colonoscopy, revealing a splenic hematoma and hemoperitoneum on a CT scan.
  • * A successful emergency splenectomy was performed, highlighting the need for emergency physicians to be aware of this potential complication for timely treatment.
View Article and Find Full Text PDF

Evidence suggests a beneficial role of the Mediterranean Diet (MedDiet) on health-related quality of life (HRQoL) in healthy subjects. HRQoL is relevant in cancer therapy and disease outcomes, therefore we investigated the association between adherence to the MedDiet and HRQoL in breast cancer survivors participating in the multicentre trial DEDiCa. Diet and HRQoL were assessed at baseline in a subgroup of 309 women enrolled within 12 months of breast cancer diagnosis without metastasis (stages I-III, mean age 52±1 yrs, BMI 27±7 kg/m2).

View Article and Find Full Text PDF